High-dose-rate interstitial brachytherapy as monotherapy in one fraction and transperineal hyaluronic acid injection into the perirectal fat for the treatment of favorable stage prostate cancer: Treatment description and preliminary results

Prada, Pedro J.; Jiménez, Isabel; González-Suárez, Herminio; Fernández, José M.; Cuervo-Arango, Covadonga; Méndez, Lucía

doi:10.1016/j.brachy.2011.05.003

Cited by 92 publications

(54 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Other centers use HDR monotherapy and the trend is to use fewer treatments -some centers are currently investigating 1 or 2 HDR implants with no IGRT [41,42]. Our clinical experience is that brachytherapy is tolerated best and has less technical limitations for men with smaller prostate volumes and with lower urinary scores at baseline [43] whereas SABR can safely treat patients with larger prostates and worse urinary scores.…”

Section: Discussionmentioning

confidence: 86%

Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: Toxicity, biochemical, and pathological outcomes

Loblaw

Cheung

D’Alimonte

et al. 2013

Radiotherapy and Oncology

159

103

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 86%

Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: Toxicity, biochemical, and pathological outcomes

Loblaw

Cheung

D’Alimonte

et al. 2013

Radiotherapy and Oncology

159

103

View full text Add to dashboard Cite

“…More recently, Prada et al (25) reported the first singlefraction HDR monotherapy in which 40 consecutive patients who had favorable localized prostate cancer were treated with 19 Gy in single fraction. The authors used a transperineal injection of hyaluronic acid into perirectal fat to increase the distance between the prostate and rectum before the treatment (26).…”

Section: Clinical Results Of High-dose-rate Monotherapymentioning

confidence: 98%

ACR Appropriateness Criteria high-dose-rate brachytherapy for prostate cancer

Hsu¹,

Yamada²,

Assimos³

et al. 2014

Brachytherapy

View full text Add to dashboard Cite

“…Meanwhile, further reports on extreme HDR-BT hypofractionation using only 3 [6] 2 [7] or only 1 fraction [8] became available with promising results regarding cancer control and acute and early late toxicity. However, due to their relatively short median follow-up of < 40 months, these results must be regarded as preliminary.…”

Section: Resultsmentioning

confidence: 99%

Late toxicity and five year outcomes after high-dose-rate brachytherapy as a monotherapy for localized prostate cancer

et al. 2014

View full text Add to dashboard Cite

BackgroundTo determine the 5-year outcome after high-dose-rate brachytherapy (HDR-BT) as a monotherapy.MethodsBetween 10/2003 and 06/2006, 36 patients with low (28) and intermediate (8) risk prostate cancer were treated by HDR-BT monotherapy. All patients received one implant and 4 fractions of 9.5 Gy within 48 hours for a total prescribed dose (PD) of 38 Gy. Five patients received concomitant androgen deprivation therapy (ADT). Toxicity was scored according to the common terminology criteria for adverse events from the National Cancer Institute (CTCAE) version 3.0. Biochemical recurrence was defined according to the Phoenix criteria and analyzed using the Kaplan Meier method. Predictors for late grade 3 GU toxicity were analyzed using univariate and multivariate Cox regression analyses.ResultsThe median follow-up was 6.9 years (range, 1.5-8.0 years). Late grade 2 and 3 genitourinary (GU) toxicity was observed in 10 (28%) and 7 (19%) patients, respectively. The actuarial proportion of patients with late grade 3 GU toxicity at 5 years was 17.7%. Late grade 2 and 3 gastrointestinal (GI) toxicities were not observed. The crude erectile function preservation rate in patients without ADT was 75%. The 5 year biochemical recurrence-free survival (bRFS) rate was 97%. Late grade 3 GU toxicity was associated with the urethral volume (p = 0.001) and the urethral V120 (urethral volume receiving ≥120% of the PD; p = 0.0005) after multivariate Cox regression.ConclusionsAfter HDR-BT monotherapy late grade 3 GU was observed relatively frequently and was associated with the urethral V120. GI toxicity was negligible, the erectile function preservation rate and the bRFS rate was excellent.

show abstract

High-dose-rate interstitial brachytherapy as monotherapy in one fraction and transperineal hyaluronic acid injection into the perirectal fat for the treatment of favorable stage prostate cancer: Treatment description and preliminary results

Cited by 92 publications

References 16 publications

Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: Toxicity, biochemical, and pathological outcomes

Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: Toxicity, biochemical, and pathological outcomes

ACR Appropriateness Criteria high-dose-rate brachytherapy for prostate cancer

Late toxicity and five year outcomes after high-dose-rate brachytherapy as a monotherapy for localized prostate cancer

Contact Info

Product

Resources

About